

ASLAN Pharmaceuticals Limited

3 Temasek Avenue
Level 18 Centennial Tower
Singapore 039190

June 18, 2024

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549

Attn: Lauren Hamill

**Re: ASLAN Pharmaceuticals Limited
Registration Statement on Form F-3
File No. 333-280145**

Acceleration Request

Requested Date: Friday, June 21, 2024

Requested Time: 4:00 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, ASLAN Pharmaceuticals Limited (the “**Registrant**”) hereby requests that the Securities and Exchange Commission (the “**Commission**”) take appropriate action to cause the above-referenced Registration Statement on Form F-3 to become effective on Friday, June 21, 2024, at 4:00 P.M. Eastern Time, or as soon thereafter as is practicable, or at such later time as its counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Carlos Ramirez and Steven Holm of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Carlos Ramirez of Cooley LLP at (858) 550-6157, or in his absence, Steven Holm of Cooley LLP at +65 6962-7528. Thank you for your assistance with this matter.

Sincerely,

ASLAN Pharmaceuticals Limited

By: /s/ Carl Firth, Ph.D.

Carl Firth, Ph.D.

Chief Executive Officer

cc: Kiran Asarpota, *ASLAN Pharmaceuticals Limited*
Carlos Ramirez, *Cooley LLP*
Steven Holm, *Cooley LLP*